Association of anti-CCP positivity and carriage of TNFRII susceptibility variant with anti-TNF-α response in rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 29, Issue 4, 2011, Pages 701-704

  Vasilopoulos, Yiannis ^a   Bagiatis, Vasilis ^a   Stamatopoulou, Dimitra ^a   Zisopoulos, Dimitris ^b   Alexiou, Ioannis ^a   Sarafidou, Theologia ^a   Settas, Loukas ^b   Sakkas, Lazaros ^a   Mamuris, Zissis ^a  

^a UNIVERSITY OF THESSALY   (Greece)

^b AHEPA UNIVERSITY HOSPITAL   (Greece)

Author keywords

Anti CCP; Anti TNF; Association; Pharmacogenetics; Polymorphism

Indexed keywords

ADALIMUMAB; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; AUTOANTIBODY; BIOLOGICAL MARKER; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE; TNFRSF1A PROTEIN, HUMAN; TNFRSF1B PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; AGED; ALLELE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG RESPONSE; FEMALE; GENOTYPE; GREECE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR NECROSIS FACTOR ALPHA GENE; TUMOR NECROSIS FACTOR RECEPTOR 1 GENE; TUMOR NECROSIS FACTOR RECEPTOR 2 GENE; BLOOD; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; DRUG ANTAGONISM; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PHENOTYPE; TIME; TREATMENT OUTCOME;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOLOGICAL MARKERS; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GREECE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; RHEUMATOID FACTOR; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80055077775     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Smolen JS, Steiner G: Therapeutics strategies for rheumatoid arthritis. Nat Rev Drug Discov 2003; 2: 473-488.
2. Strand V, Kimberly R, Isaacs JD: Biologic therapies in rheumatology: lessons learned, future directions. Nat Rev Drug Discov 2007; 6: 75-92.
3. Plenge RM, Criswell LA: Genetic variants that predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis: current challenges and future directions. Curr Opin Rheumatol 2008; 20: 145-152.
4. Braun-Moscovici Y, Markovits D, Zinder O et al.: Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis. J Rheumatol 2006; 33: 497-500.
5. Mugnier B, Balandraud N, Darque A et al.: Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum 2003; 48: 1849-1852.
6. Fonseca JE, Carvalho T, Cruz M et al.: Polymorphism at position -308 of the tumour necrosis factor alpha gene and rheumatoid arthritis pharmacogenetics. Ann Rheum Dis 2005; 64: 793-794.
7. Seitz M, Wirthmuller U, Moller B, Villiger PM: The -308 tumour necrosis factor- {alpha}gene polymorphism predicts therapeutic response to TNF{alpha}-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford) 2007; 46: 93-96.
8. Maxwell JR, Potter C, Hyrich KL et al.: Association of the tumour necrosis factor - 308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Hum Mol Genet 2008; 17: 3532-3538.
9. Lee YH, Ji JD, Bae SC, Song GG: Associations between tumor necrosis factor-alpha (TNFalpha) -308 and -238 G/A polymorphisms and shared epitope status and responsiveness to TNF-alpha blockers in rheumatoid arthritis: a metaanalysis update. J Rheumatol 2010; 37: 740-746.
10. Bobbio-Pallavicini F, Caporali R, Alpini C et al.: High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis. Ann Rheum Dis 2007; 66: 302-7.
11. Morozzi G, Fabbroni M, Bellisai F et al.: Low serum level of COMP, a cartilage turnover marker, predicts rapid and high ACR70 response to adalimumab therapy in rheumatoid arthritis. Clin Rheumatol 2007; 26: 1335-8.
12. Alessandri C, Bombardieri M, Papa N et al.: Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNF-alpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis 2004: 63: 1218-21.
13. Potter C, Hyrich KL, Tracey A et al.: Association of rheumatoid factor and anticyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis 2009; 68: 69-74.
14. Kooloos WM, De Jong DJ, Huizinga TW, Guchelaar HJ: Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease. Drug Discov Today 2007; 12: 125-131.
15. Van Gestel AM, Prevoo ML, Van't Hof MA et al.: Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996; 39: 34-40.
16. Prevoo ML, VAN't Hof MA, Kuper HH et al.: Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44-48.
17. Lin DY, HU Y, Huang BE: Simple and efficient analysis of disease association with missing genotype data. Am J Hum Genet 2008; 82: 444-452.
18. Hyrich KL, Watson KD, Silman AJ, Symmons DP: Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2006; 45: 1558-1565.
19. Fabris M, Tolusso B, DI POI E et al.: Tumor necrosis factor-alpha receptor II polymorphism in patients from southern Europe with mild-moderate and severe rheumatoid arthritis. J Rheumatol 2002; 29: 1847-1850.
20. Glossop JR, Dawes PT, Nixon NB, Mattey DL: Polymorphism in the tumour necrosis factor receptor II gene is associated with circulating levels of soluble tumour necrosis factor receptors in rheumatoid arthritis. Arthritis Res Ther 2005; 7: R1227-R1234.